StockIQ.techBoston Scientific Corporation (BSX) Stock Analysis
Free AI-powered analysis and research for Boston Scientific Corporation stock
Sector: Healthcare
BSX snapshot
Data as of 3 Nov 2026 close. Updated daily.
Boston Scientific Corporation scores 26/100 on StockIQ's model, which reads as negative signals overall. The price is below its 200-day average and at 7% of its 52-week range, down 55.5% over the past year. Latest reported figures show a profit margin of 16.6% and revenue growth of +1.4%.
What is driving the score
- RSI Neutral: +5
- Downtrend: -5
- MACD Bearish: -8
- Good Profit Margin (16.6%): +5
- Long-term Downtrend: -8
- Severe Underperformance (-55.5% over 1 year): -10
- Low Volume (0.4x): -3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full BSX report
Boston Scientific Corporation (BSX) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze BSX Now →📰 Latest Update
Is BSX Worth Buying Now as Low Valuation Meets Weak Earnings Growth?
Tue, November 3, 2026 at 1:21 PM UTC 3 min read
Boston Scientific Corp. (BSX) is currently trading at a low valuation, with a forward price-to-earnings ratio of 14.06, significantly below its five-year median of 25.08. However, the company faces weak earnings growth, as management anticipates 2027 to be the trough of the current cycle, with a more substantial performance improvement expected in 2028. Despite having valuable franchises and a promising innovation pipeline, the article suggests that the current setup favors patience due to execution risks and competitive pressures.